Clinical Trials & COVID-19

Has your doctor talked to you about
liver scarring due to nonalcoholic steatohepatitis (NASH)?

NASH is a common form of liver disease caused by fat cells stored in the liver. In people with NASH, fat cells damage the liver and cause fibrosis (scarring), which can lead to cirrhosis (severe scarring) and eventually liver cancer. Mild liver scarring may not have symptoms, but severe liver scarring can eventually cause the liver to shut down.

If you’ve been diagnosed with compensated cirrhosis due to NASH, learn about the Symmetry study, a NASH clinical trial. The Symmetry study is evaluating an investigational drug called efruxifermin (EFX) to find out if it can reverse liver damage in people with compensated cirrhosis due to NASH.

The Symmetry Study